Abstract 16019: MRI Venous Volume Measurements are Associated With Ankle Brachial Index in Peripheral Artery Disease Patients: Results From the Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention Trial (ELIMIT)
Introduction: The relationship between peripheral artery disease (PAD) and the venous system remains poorly understood. The objective of this secondary analysis of ELIMIT was to assess the association between magnetic resonance imaging (MRI) based superficial femoral vein (SFV) volumes and measures of PAD in patients randomized to triple lipid modification therapy (simvastatin, ezetimibe, niacin) versus mono therapy (simvastatin).
Hypothesis: We hypothesized that SFV volume measurements are associated with PAD due to the relationship between arterial and venous flow.
Methods: SFV wall, lumen, and total volumes were quantified by MRI in all available ELIMIT scans (79 patients) and analyzed by drug groups and changes over 2-years. Pooled linear regression analyses were performed to assess the associations of SFV measures with ABI, measures of the superficial femoral artery (SFA), and maximum walking time (MWT).
Results: There were no significant differences at baseline or for the 24-month changes in SFV volumes between drug groups (Table). MWT did not differ by drug group at baseline or over 2-years (p=0.16). When drug groups were combined, linear regression analyses showed a direct association between baseline SFA total vessel volumes and SFV wall (r=0.46, p<0.0001), SFV lumen (r=0.42, p=0.0001), and SFV total volumes (r=0.46, p<0.0001). Baseline ABI values were linearly correlated with SFV wall (r=0.27, p=0.027), SFV lumen (r=0.27, p=0.028), and SFV total volumes (r=0.28, p=0.022). Body mass index was also directly associated with SFV wall (r=0.31, p=0.006), lumen (r=0.26, p=0.019), and total volumes (r=0.29, p=0.009). The 2-year change in MWT was inversely associated with 24-month changes in SFV total volumes (r=-0.45, p=0.03).
Conclusions: SFA atheroma burden is positively associated with superficial femoral vein volumes, indicating that PAD affects the venous system. Enlarged SFV volumes at 2-years are associated with shorter maximum walking time.
Author Disclosures: H. Kamran: None. V. Nambi: None. S. Negi: None. E.Y. Yang: None. C. Chen: None. S.S. Virani: None. P. Kougias: None. A.B. Lumsden: None. J.D. Morrisett: None. C.M. Ballantyne: Consultant/Advisory Board; Significant; Merck, Pfizer. G. Brunner: None.
- © 2014 by American Heart Association, Inc.